Lantheus Holdings, Inc. (LNTH)

Market Cap	4.47B
Revenue (ttm)	1.30B
Net Income (ttm)	326.66M
Shares Out	68.55M
EPS (ttm)	4.65
PE Ratio	14.02
Forward PE	9.72
Dividend	n/a
Ex-Dividend Date	n/a

Volume	602,997
Open	63.02
Previous Close	65.21
Day's Range	63.76 - 65.27
52-Week Range	50.20 - 100.85
Beta	0.54
Analysts	Strong Buy
Price Target	101.00 (+54.91%)
Earnings Date	May 2, 2024

About LNTH

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or r...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Jun 25, 2015
• Employees: 834
• Stock Exchange: NASDAQ
• Ticker Symbol: LNTH

Financial Performance

In 2023, LNTH's revenue was $1.30 billion, an increase of 38.65% compared to the previous year's $935.06 million. Earnings were $326.66 million, an increase of 1063.86%.

Analyst Forecast

According to 7 analysts, the average rating for LNTH stock is "Strong Buy." The 12-month stock price forecast is $101.0, which is an increase of 54.91% from the latest price.

Price Target

$101.0

(54.91% upside)

Analyst Consensus: Strong Buy